Ordering and Prescribing

Learn about ordering and prescribing CINRYZE and other support services through the CINRYZESolutions Support Program.

Self-Administration Option

Hands-on self-administration training for your eligible patients is available through the Path to Independence™ Program.

Looking for Solid Facts?

Review the CINRYZE Clinical Trial Data and learn more about CINRYZE.

INDICATION
CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

IMPORTANT SAFETY INFORMATION
CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.

Severe hypersensitivity reactions may occur. Because hypersensitivity reactions and HAE attacks may have similar symptoms, distinguishing between the two is important. Epinephrine should be immediately available to treat any acute severe hypersensitivity reaction and CINRYZE should be discontinued.

Thrombotic events have been reported in patients receiving CINRYZE for routine prophylaxis and in patients receiving C1 esterase inhibitor products when used off-label at high doses. Monitor patients with known risk factors for thrombotic events.

CINRYZE is made from human plasma. Products made from human plasma may contain infectious agents (e.g. viruses and, theoretically, the Creutzfeldt-Jakob Disease agent). The risk that such products will transmit an infectious agent has been reduced by screening donors, testing for the presence of infections, and by inactivating or removing a broad range of viruses during the manufacturing process.

In the clinical trial, the most common adverse reactions observed by ≥ 5% of the 24 evaluable subjects after receiving CINRYZE were upper respiratory tract infection, sinusitis, rash, and headache.

Before prescribing CINRYZE, please read the Full Prescribing Information.

Reference
  1. Lunn, ML,Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol. 2010;104:211-214.
  2. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López-Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94:498-503.
  3. Zuraw BL. Hereditary Angioedema. N Engl J Med. 2008;359:10:1027-1036.